API

A steroid is a type of organic compound that contains...

read more...

Pharma Intermediate

Pharmaceuticals refer to the drugs and medicines...

read more...

Speciality Chemicals

Specialty chemicals are those chemicals which is produced...

read more...

Products Under Devp.

New Products Under Development In response...

read more...

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2011
(Rs. In Lacs except per share data)
PARTICULARS For the Quarter Ended For the  Quarter Ended For the  Year Ended For the  Year Ended Consolidated For  the Year Ended Consolidated  For  the Year Ended
31st Mar 2011 31st Mar 2010 31st Mar 2011 31st Mar 2010 31st Mar 2011 31st Mar 2010
(Gross) Sales / Income from operations 15,102 13,428 52,301 49,695 52,752 50,408
Less : Excise Duty & Sales Tax 767 736 2,659 2,553 2,647 2,557
1. (a) (Net) Sales / Income from operations 14,335 12,692 49,642 47,142 50,105 47,850
(b) Other Operating Income - - - - - -
2. Expenditure
(a). (Increase) / Decrease in stock in trade 352 400 (1,618) 376 (1,870) 316
(b). Consumption of raw materials. 7,985 5,932 27,300 23,179 27,666 23,177
(c). Purchase of Traded Goods 1,849 2,258 8,421 8,202 7,633 7,732
(d). Employees cost 432 351 1,646 1,362 1,993 1,477
(e). Depreciation 417 348 1,548 1,352 1,911 1,703
(f). Other expenditure 2,158 1,901 7,858 6,859 7,985 7,108
(g). Total Expenditure 13,193 11,190 45,155 41,330 45,318 41,513
3. Profit from Operations before Other Income,    interest and exceptional items 1,142 1,501 4,487 5,811 4,787 6,337
4. Other Income 1 11 8 45 16 63
5. Profit before Interest & Exceptional Items 1,143 1,512 4,495 5,856 4,803 6,400
6. Interest 409 331 1,348 1,474 1,492 1,660
7. Profit after Interest but before Exceptional Items 734 1,181 3,147 4,382 3,311 4,740
8. Exceptional Items - - - - - -
9. Profit from Ordinary Activities before Tax 734 1,181 3,147 4,382 3,311 4,740
10. Tax Expenses (Includes) 105 458 900 1,772 961 1,896
Provision for Taxation 64 391 650 1,502 792 1,642
Provision for Deffered Taxation 41 68 250 270 169 254
11. Net profit from ordinary Activities after Tax 629 723 2,247 2,610 2,350 2,844
12. Extraodinary Item (net of tax expenses )
13. Net Profit for the period 629 723 2,247 2,610 2,350 2,844
Less
a) Minority Interest - - - - - 38
b) Adjustment on Consolidation - - - - 9 3
c) Share of Profit/(Loss) in Associate - - - - 30 19
Profit After Consolidation adjustment 629 723 2,247 2,610 2,371 2,823
14. Paid-up Equity Share Capital of Rs.10/- each. 1,211 1,211 1,211 1,211 1,211 1,211
15. Reserves & Surplus (excluding revaluation reserves) - - 14,441 12,898 15,105 13,434
16. Basic E P S (in Rs.) 5.19 5.97 18.56 22.08 19.58 23.88
17. Public Shareholding
Number of Shares 5569613 6051226 5569613 6051226 5569613 6051226
Percentage of Total Shareholding 46.00 49.97 46.00 49.97 46.00 49.97
18. Promoters & Promoter Group
Shareholding**
a) Pledged/Encumbered
- Number of Shares NIL NIL NIL NIL NIL NIL
-Percentage of shares( as a percentage of the NIL NIL NIL NIL NIL NIL
total shareholding of promoter and promoter group)
-Percentage of shares( as a percentage of NIL NIL NIL NIL NIL NIL
total sharecapital of the Company)
b) Non-encumbered
- Number of Shares 6538937 6057324 6538937 6057324 6538937 6057324
-Percentage of shares( as a percentage of 100 100 100 100 100 100
total shareholding of promoter and promoter group)
-Percentage of shares( as a percentage of 54.00 50.03 54.00 50.03 54.00 50.03
total sharecapital of the Company)

Notes :

 

1. The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 25th May 2011.

2. The Board of Directors has recommended Final Dividend of Rs.2.5/-per share (25%) on 1,21,08,550 Equity shares of Rs.10/- each fully paid-up for the Financial year 2010-11.

3. Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement as per AS - 17 'Segment Reporting' is not attracted.

4. Figures of the previous periods have been regrouped and rearranged wherever necessary.

5. Number of Investors complaints (i) pending at the begaining of quarter 2 (ii) received during the quarter : 1 (Iii) redressed : 3 (iv) pending at the end of the quarter : 0.


For and on behalf of the Board
FOR AARTI DRUGS LIMITED
Place : Mumbai
Harshit M Savla
DATE : 25th May, 2011
(Jt. Managing Director)
 

Resource Download

Annual Report
Click here to download
annual report
Investor Presentation
Click here to download
Presentation

Copyright © 2010 Aarti Drugs Ltd. All Rights Reserved
Website Developed by : Sri Hema Infotech